NO inhibits arterial injury after vascular procedures via adventitial stem cells

NO 通过外膜干细胞抑制血管手术后的动脉损伤

基本信息

  • 批准号:
    8255507
  • 负责人:
  • 金额:
    $ 38.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-11 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Neointimal hyperplasia is a significant problem that results in the failure of vascular interventions. The classic arterial injury response that leads to the development of neointimal hyperplasia describes processes involving the intima and media with a relative lack of involvement of the adventitia. However, the adventitia is no longer considered a simple structural component of the arterial wall. In the last decade, research has shown that many cell types from the adventitia actively regulate and contribute to the development of neointimal hyperplasia, including resident and circulating adventitial stem and progenitor cells. We, and others, have demonstrated that NO is a potent inhibitor of neointimal hyperplasia through regulating different aspects of the classic arterial injury response. However, little is known about how NO affects the adventitial layer of the arterial wall following injury. We have recently assessed the cellular response throughout the arterial wall to injury and exposure to NO. Interestingly, while NO prevents the development of neointimal hyperplasia and delays repopulation of the media, we were surprised to find that NO actually increases cellularity in the adventitia. This increase in cellularity is not due to an increase in vascular smooth muscle cells, fibroblasts, myofibroblasts, or inflammatory cells, but may in fact be due to an increase in Sca1+ progenitor cells, among others. Thus, given the important role of the adventitia in regulating the arterial injury response, recent discoveries of the role of stem and progenitor cells in this process, and our preliminary data, we hypothesize that NO inhibits neointimal hyperplasia by regulating recruitment and phenotypic differentiation of resident and circulating adventitial stem and progenitor cells following injury. Furthermore, we hypothesize that NO supports differentiation of adventitial stem and progenitor cells into endothelial-like cells, contributing to adventitial neovascularity. To investigate these hypotheses, our specific aims are: 1) to characterize the effect of NO on Sca1+, CD34+, and flk-1+ adventitial stem and progenitor cell populations following arterial injury in vivo; 2) to determine the effect of NO on Sca1+, CD34+, and flk-1+ adventitial cell populations in vitro; and 3) to manipulate Sca1+, CD34+, and flk-1+ adventitial cell populations in vivo to determine if NO-mediated inhibition of neointimal hyperplasia following arterial injury is dependent on these adventitial cell populations. The innovative studies described in this proposal will result in a change in how we think about the adventitia and the vascular biology of NO, and provide a novel mechanism by which NO regulates neointimal hyperplasia that will lead to the development of new strategies to prevent neointimal hyperplasia and restenosis following vascular interventions. PUBLIC HEALTH RELEVANCE: Recent studies have uncovered the importance of the adventitia as well as resident and circulating stem and progenitor cells in mediating the arterial injury response that leads to the development of neointimal hyperplasia. Nitric oxide (NO) is a potent inhibitor of neointimal hyperplasia, but little is known about how NO affects the adventitial layer of the arterial wall following injury. The studies in this proposal will elucidate the role of adventitial stem and progenitor cells in mediating the beneficial effects of NO in the vasculature and will result in a change in how we think about the adventitia and the vascular biology of NO thereby allowing the development of new strategies to prevent neointimal hyperplasia and restenosis following vascular interventions.
描述(由申请人提供):新生内膜增生是导致血管介入失败的重要问题。导致新生内膜增生的经典动脉损伤反应描述了涉及内膜和中膜的过程,相对缺乏外膜的参与。然而,外膜不再被认为是动脉壁的简单结构组成部分。在过去的十年中,研究表明,来自外膜的许多细胞类型积极调节并促进新生内膜增生的发展,包括驻留和循环外膜干细胞和祖细胞。我们和其他人已经证明,NO是一种有效的抑制剂,通过调节不同方面的经典动脉损伤反应的新生内膜增生。然而,很少有人知道NO如何影响动脉壁外膜层损伤后。我们最近评估了整个动脉壁对损伤和暴露于NO的细胞反应。有趣的是,虽然NO可以防止新生内膜增生的发展并延迟中膜的再增殖,但我们惊讶地发现NO实际上增加了外膜的细胞构成。这种细胞构成的增加不是由于血管平滑肌细胞、成纤维细胞、肌成纤维细胞或炎性细胞的增加,而实际上可能是由于Sca 1+祖细胞等的增加。因此,考虑到外膜在调节动脉损伤反应中的重要作用,干细胞和祖细胞在此过程中的作用的最新发现,以及我们的初步数据,我们假设NO通过调节损伤后驻留和循环外膜干细胞和祖细胞的募集和表型分化来抑制新生内膜增生。此外,我们假设NO支持外膜干细胞和祖细胞分化为内皮样细胞,促进外膜新生血管形成。为了研究这些假设,我们的具体目标是:1)在体内表征NO对动脉损伤后的Sca 1+、CD 34+和flk-1+外膜干细胞和祖细胞群的影响; 2)在体外确定NO对Sca 1+、CD 34+和flk-1+外膜细胞群的影响;和3)在体内操作Sca 1+、CD 34+和flk-1+外膜细胞群,以确定NO介导的动脉损伤后新生内膜增生的抑制是否依赖于这些外膜细胞群。本提案中描述的创新研究将导致我们如何看待NO的外膜和血管生物学的变化,并提供一种新的机制,NO通过该机制调节新生内膜增生,这将导致开发新的策略来预防血管介入后的新生内膜增生和再狭窄。 公共卫生关系:最近的研究已经揭示了外膜以及驻留和循环干细胞和祖细胞在介导导致新生内膜增生发展的动脉损伤反应中的重要性。一氧化氮(NO)是一种有效的抑制新生内膜增生,但很少有人知道NO如何影响外膜层的动脉壁损伤后。本提案中的研究将阐明外膜干细胞和祖细胞在介导NO在血管系统中的有益作用中的作用,并将导致我们如何看待NO的外膜和血管生物学的变化,从而允许开发新的策略来预防血管介入后的新生内膜增生和再狭窄。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Melina Rae Kibbe其他文献

Melina Rae Kibbe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Melina Rae Kibbe', 18)}}的其他基金

Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment
开发多模式靶向纳米治疗药物以预防动脉粥样硬化环境中的再狭窄
  • 批准号:
    10667411
  • 财政年份:
    2022
  • 资助金额:
    $ 38.13万
  • 项目类别:
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment
开发多模式靶向纳米治疗药物以预防动脉粥样硬化环境中的再狭窄
  • 批准号:
    10364365
  • 财政年份:
    2022
  • 资助金额:
    $ 38.13万
  • 项目类别:
Novel in situ custom biodegradable drug-eluting stents for endovascular surgery
用于血管内手术的新型原位定制可生物降解药物洗脱支架
  • 批准号:
    9892106
  • 财政年份:
    2020
  • 资助金额:
    $ 38.13万
  • 项目类别:
A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ
一种原位去除动脉粥样硬化斑块病变的新型血管内方法
  • 批准号:
    10084300
  • 财政年份:
    2019
  • 资助金额:
    $ 38.13万
  • 项目类别:
A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ
一种原位去除动脉粥样硬化斑块病变的新型血管内方法
  • 批准号:
    10577344
  • 财政年份:
    2019
  • 资助金额:
    $ 38.13万
  • 项目类别:
Bioengineering Catalytically Active Grafts for Vascular Surgery
用于血管手术的生物工程催化活性移植物
  • 批准号:
    8737475
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
Bioengineering Catalytically Active Grafts for Vascular Surgery
用于血管手术的生物工程催化活性移植物
  • 批准号:
    8967095
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
Bioengineering Catalytically Active Grafts for Vascular Surgery
用于血管手术的生物工程催化活性移植物
  • 批准号:
    9794740
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
Bioengineering Catalytically Active Grafts for Vascular Surgery
用于血管手术的生物工程催化活性移植物
  • 批准号:
    9275408
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
Novel Vehicles for Targeted Cardiovascular Repair
用于靶向心血管修复的新型载体
  • 批准号:
    8579683
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:

相似海外基金

Development of a balloon angioplasty catheter capable of simultaneous endovascular delivery of liquid therapeutic agents into the vascular wall
开发能够同时将液体治疗剂血管内输送到血管壁的球囊血管成形术导管
  • 批准号:
    10324960
  • 财政年份:
    2021
  • 资助金额:
    $ 38.13万
  • 项目类别:
Simplified Transfemoral Carotid Angioplasty and Stenting Under FlowReversal Using a Novel Combination Access Sheath/Balloon System
使用新型组合通路鞘/球囊系统在血流逆转下简化经股颈动脉血管成形术和支架置入术
  • 批准号:
    10081007
  • 财政年份:
    2020
  • 资助金额:
    $ 38.13万
  • 项目类别:
Balloon Angioplasty Inflation Device
球囊血管成形术充气装置
  • 批准号:
    10019316
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
Elucidation of appropriate patients for percutaneous transluminal renal angioplasty treatment
阐明适合经皮腔内肾血管成形术治疗的患者
  • 批准号:
    17K09743
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Novel Angioplasty Catheter for Treatment of Calcified Arteries
开发用于治疗钙化动脉的新型血管成形术导管
  • 批准号:
    MR/P026850/1
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Research Grant
Balloon Angioplasty Inflation Device
球囊血管成形术充气装置
  • 批准号:
    9410026
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease
治疗性血管生成加血管成形术和支架置入术治疗肾血管疾病的临床前试验
  • 批准号:
    9249339
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
Basic research about application of liposomes to prevent stenosis after angioplasty of craniocervical artery stenosis
应用脂质体预防颅颈动脉狭窄血管成形术后狭窄的基础研究
  • 批准号:
    25462205
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Utility Of Adenosine Stress Cardiac Magnetic Resonance Imaging Following ST Elevation Myocardial Infarction Post Primary Angioplasty
ST 段抬高型心肌梗死初次血管成形术后腺苷应激心脏磁共振成像的效用
  • 批准号:
    nhmrc : 1018161
  • 财政年份:
    2011
  • 资助金额:
    $ 38.13万
  • 项目类别:
    NHMRC Postgraduate Scholarships
Novel Approaches in Treatment of Vascular Injury Following Balloon Angioplasty
治疗球囊血管成形术后血管损伤的新方法
  • 批准号:
    8402612
  • 财政年份:
    2011
  • 资助金额:
    $ 38.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了